Arovella Therapeutics Ltd (AU:ALA) — Market Cap & Net Worth
Market Cap & Net Worth: Arovella Therapeutics Ltd (ALA)
Arovella Therapeutics Ltd (AU:ALA) has a market capitalization of $60.73 Million (AU$85.82 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #21180 globally and #728 in its home market, demonstrating a 7.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arovella Therapeutics Ltd's stock price AU$0.07 by its total outstanding shares 1208783672 (1.21 Billion). Review ALA total debt and obligations to assess the company's total debt and financial obligations.
Arovella Therapeutics Ltd Market Cap History: 2015 to 2026
Arovella Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $425.94 Million to $60.73 Million (-17.50% CAGR).
Arovella Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arovella Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
584.87x
Arovella Therapeutics Ltd's market cap is 584.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $315.52 Million | $5.79 Million | -$2.23 Million | 54.53x | N/A |
| 2017 | $252.40 Million | $7.22 Million | -$1.24 Million | 34.95x | N/A |
| 2018 | $103.23 Million | $425.86K | -$5.46 Million | 242.41x | N/A |
| 2019 | $41.99 Million | $1.22 Million | -$7.80 Million | 34.45x | N/A |
| 2020 | $34.21 Million | $532.69K | -$9.94 Million | 64.22x | N/A |
| 2021 | $33.36 Million | $257.35K | -$5.05 Million | 129.62x | N/A |
| 2022 | $19.67 Million | $295.81K | -$8.62 Million | 66.50x | N/A |
| 2023 | $98.36 Million | $405.90K | -$10.18 Million | 242.32x | N/A |
| 2024 | $145.40 Million | $17.00K | -$8.75 Million | 8552.91x | N/A |
| 2025 | $79.54 Million | $136.00K | -$7.51 Million | 584.87x | N/A |
Competitor Companies of ALA by Market Capitalization
Companies near Arovella Therapeutics Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Arovella Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Arovella Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Arovella Therapeutics Ltd's market cap moved from $425.94 Million to $ 60.73 Million, with a yearly change of -17.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$60.73 Million | -23.66% |
| 2025 | AU$79.54 Million | -45.29% |
| 2024 | AU$145.40 Million | +47.83% |
| 2023 | AU$98.36 Million | +400.00% |
| 2022 | AU$19.67 Million | -41.03% |
| 2021 | AU$33.36 Million | -2.50% |
| 2020 | AU$34.21 Million | -18.53% |
| 2019 | AU$41.99 Million | -59.32% |
| 2018 | AU$103.23 Million | -59.10% |
| 2017 | AU$252.40 Million | -20.01% |
| 2016 | AU$315.52 Million | -25.92% |
| 2015 | AU$425.94 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Arovella Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.73 Million USD |
| MoneyControl | $60.73 Million USD |
| MarketWatch | $60.73 Million USD |
| marketcap.company | $60.73 Million USD |
| Reuters | $60.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more